TAK$20.880.14%-0.03
After Hours: 20.74-0.14 -0.67%
Takeda Pharmaceutical Co Adr (TAK)
Date: 2026-11-02 16:00O: 20.88H: 21.17L: 20.78C: 20.88Vol: 2.382M
Takeda Pharmaceutical Co Adr stock is traded at $20.88, with a volume of 2,382,431. It is down -0.14% in the last 24 hours and up +16.91% over the past month. Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
Previous Close:
$20.91
Open:
$20.88
24h Volume:
2,382,431
Relative Volume:
0.80
Market Cap:
$66.71B
Revenue:
$29.91B
Net Income/Loss:
$1.30B
P/E Ratio:
51.48
EPS:
$0.4056
Net Cash Flow:
$3.49B
1W Performance:
+2.20%
1M Performance:
+16.91%
6M Performance:
+25.63%
1Y Performance:
+55.36%
1-Day Range:
$20.78$21.17
1-Week Range:
$19.50$21.22
52-Week Range:
$13.35$21.22
Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile
Compare TAK vs TEVA, HLN, ZTS, UTHR
| Stocks | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|
TAK Takeda Pharmaceutical Co Adr | $66.71B | $29.91B | $1.30B | $3.49B | $0.4056 |
 TEVA Teva Pharmaceutical Industries Ltd Adr | $47.47B | $14.10B | $706.00M | $1.35B | $1.35 |
 HLN Haleon Plc Adr | $38.59B | $14.54B | $2.22B | $2.58B | $0.4871 |
 ZTS Zoetis Inc | $34.38B | $9.52B | $2.62B | $2.37B | $6.04 |
 UTHR United Therapeutics Corp | $25.55B | $3.15B | $1.31B | $1.09B | $27.09 |
Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades
Takeda Pharmaceutical Co Adr Stock (TAK) Financials Data
There is no financial data for Takeda Pharmaceutical Co Adr (TAK). Check out other stocks for more information.
Takeda Pharmaceutical Co Adr Stock (TAK) Insider Trading
- Platford Giles RichardNov 01 '26President, International Busin
- Transaction
- Proposed Sale
- Cost
- $20.17
- #Shares
- 55,617
- Value ($)
- 1,121,795
- #Shares Total
- 0
- Teresa BitettiNov 01 '26President, Global Oncology Bus
- Transaction
- Proposed Sale
- Cost
- $20.17
- #Shares
- 46,609
- Value ($)
- 940,104
- #Shares Total
- 0
- Duprey Lauren RusckowskiSep 14 '26Chief Transformation Officer
- Transaction
- Sale
- Cost
- $18.54
- #Shares
- 34,535
- Value ($)
- 640,279
- #Shares Total
- 191,522
- Lauren Rusckowski DupreySep 10 '26Chief Transformation Officer
- Transaction
- Proposed Sale
- Cost
- $18.37
- #Shares
- 34,535
- Value ($)
- 634,408
- #Shares Total
- 0
- Plump Andrew StewartSep 02 '26Officer
- Transaction
- Proposed Sale
- Cost
- $18.49
- #Shares
- 116,191
- Value ($)
- 2,148,372
- #Shares Total
- 0
- Plump Andrew StewartSep 02 '26President, R&D
- Transaction
- Sale
- Cost
- $18.49
- #Shares
- 116,191
- Value ($)
- 2,148,372
- #Shares Total
- 145,465
- Plump Andrew StewartAug 19 '26President, R&D
- Transaction
- Sale
- Cost
- $18.49
- #Shares
- 19,651
- Value ($)
- 363,347
- #Shares Total
- 261,656
- Plump Andrew StewartAug 19 '26Officer
- Transaction
- Proposed Sale
- Cost
- $18.49
- #Shares
- 19,651
- Value ($)
- 363,348
- #Shares Total
- 0
- Greenway Nicola Deidre PetalAug 18 '26Chief Human Resources Officer
- Transaction
- Sale
- Cost
- $18.11
- #Shares
- 12,980
- Value ($)
- 235,118
- #Shares Total
- 40,049
- Nicola GreenwayAug 14 '26Chief Human Resources Officer
- Transaction
- Proposed Sale
- Cost
- $17.39
- #Shares
- 12,980
- Value ($)
- 225,722
- #Shares Total
- 0
